Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Daniel Victor Ortigoza: Lower Bleeding Rates with Apixaban in Acute VTE Treatment
Daniel Victor Ortigoza/LinkedIn
Jul 25, 2026, 07:03

Daniel Victor Ortigoza: Lower Bleeding Rates with Apixaban in Acute VTE Treatment

Daniel Victor Ortigoza, Vice Chair of the Argentine Federation of Cardiology’s Cardio-Oncology Committee, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine, adding:

“Bleeding Risk with Apixaban versus Rivaroxaban in Acute Venous Thromboembolism.

Patients with acute symptoms of pulmonary embolism or proximal deep vein thrombosis who were to receive apixaban or rivaroxaban for 3 months were included.

Apixaban was administered at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily, and rivaroxaban at a dose of 15 mg twice daily for 21 days, followed by 20 mg daily.

The primary outcome measure was clinically relevant bleeding (CRB)-a composite of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) according to the definitions of the International Society on Thrombosis and Haemostasis (ISTH).

A primary event occurred in 44 of 1,345 patients (3.3 percent) in the apixaban group and in 96 of 1,355 (7.1 percent) in the rivaroxaban group (relative risk: 0.46; 95 percent confidence interval [CI]: 0.33 to 0.65; P less than 0.001)

Central figure: Clinically Relevant Bleeding.

Shown are Kaplan–Meier curves for the first episode of clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, during the 3-month treatment period (primary outcome).

The inset shows the same data on an enlarged y-axis.

Shading indicates 95 percent confidence intervals.”

Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger

Daniel Victor Ortigoza: Lower Bleeding Rates with Apixaban in Acute VTE Treatment

Stay updated on all scientific advances with Hemostasis Today.

Abbey Willcox Acute VTE Alejandro Lazo-Langner Apixaban Benoit Côté Clive Kearon Daniel Victor Ortigoza Deepa Suryanarayan Erik Yeo Erin Thomas Etimbuk Umana Fionnuala Ní Áinle Genevieve Le Templier Gregoire Le Gal Health Helen J. Crowther Hematology Hemostasis Hemostasis News Hemostasis Today Huyen A. Tran ISTH James Douketis Jean-Philippe Galanaud Kerstin de Wit Lisa Baumann Kreuziger Marc Blondon Marc Rodger Medicine Michael J. Kovacs Peter Greenstreet Ritam Prasad Rivaroxaban Sam Schulman Stefano Barco Sudeep Shivakumar Susan Kahn Susan Solymoss The New England Journal of Medicine Tim Ramsay Tobias Tritschler Tony Wan Vivien M. Chen
NewsFeed